Trygg Returns to Ogilvy to Lead Creative
Toby Trygg has rejoined the Ogilvy team as the Executive Creator Director in Ogilvy Health’s New York City headquarters. He began his career 20 years ago as an Art Director at Oglivy and has since become a master in consumer marketing and creative. He will oversee creative teams to drive cutting-edge brand identities and execute breakthrough healthcare marketing campaigns. Facebook recognizes him as one of the top 15 social thought leaders in pharma and he is also a member of their Health Advisory Panel, which pioneers the use of new media and technologies in partnerships with new media outlets and platforms including Facebook, Google, and Snapchat.
“As the lines between healthcare and consumer marketing continue to blur,” he says, “it’s important to have access to the best and brightest from both disciplines.”
Diana Scott Joins Finn Partners
Industry veteran Diana Scott joins Finn Partners, a leading, global, integrated marketing agency, as a Partner in its Health Practice. She brings 20 years of experience partnering with clients across oncology, cardiometabolic disease, and more. She possesses insight on a range of client communications needs, having led major global communication agencies through pharmaceutical portfolio programs, brand launches, and disease awareness campaigns. Scott joins Finn from Porter Novelli, where she oversaw one of the agency’s largest oncology accounts.
“Advances in care are becoming so personalized, and are happening so quickly, that they can actually hinder patients’ ability to make treatment decisions, but companies and advocates can cut through the noise and provide value,” Scott said in a statement. “The Finn Partners team shares my passion for helping clients build communities and content that empowers patients and ultimately, improve people’s lives.”
As Miles White steps down from the CEO position, Robert Ford, current President and Chief Operating Officer, will step in. Ford is an expert in the pharma franchise’s newest target—emerging markets and medical devices. Ford was instrumental in the success of the FreeStyle Libre glucose monitor, now Abbott’s top growth driver. During his three years at the company, he also led the $25 billion acquisition of St. Jude Medical, whose cardiovascular solutions are a major part of its medical device division.
Javier San Martin, MD steps in as Chief Medical Officer of the RNA biotech along with Curt Bradshaw, PhD, the new Chief Scientific Officer. Dr. San Martin previously served as Senior Vice President and Head of Global Clinical Development at Ultragenyx. He is an expert in leading the medical, regulatory and clinical operations of global clinical programs.
Dr. Bradshaw most recently served as President, CSO, and Board Member for Tollnine, a company he co-founded to develop antibody conjugates for immuno-oncology. He has played leading roles at a number of biotech institutions including Solstice Biologics, where he worked on siRNA tech. Both will provide strategic and operational guidance to research and development teams as Arrowhead advances a growing pipeline of RNAi therapeutics.
Amygdala Neurosciences, Inc.
The company developing pharmacotherapy for substance abuse names Mack Mitchell, MD as Chief Medical Officer. With two decades of research leadership experience, Dr. Mitchell is expected to lead ANS-6637 Phase II studies for opioid, alcohol, and smoking/nicotine use disorders. He also serves as a member of Amygdala’s Board of Directors.
Conatus Pharmaceuticals Inc.
Kathleen Scott is appointed as an independent member of the Board of Directors for Conatus. She brings 25 years of experience in finance, accounting, and private company restructuring to the rare disease biotech company. Scott is currently a Managing Director at Hale BioPharma Ventures, and Chief Financial Officer for some of its portfolio companies in the life sciences industry.
Industry veteran John Reid is the new Chief Creative Director at McCann Health New Jersey. Reid is an internationally recognized creative guru, having worked with big league clients such as AstraZeneca, Pfizer, Nike, and Microsoft. He previously served as Chief Creative Director and EVP at Razorfish Health. At McCann Health, he will also serve as a member of the network’s global Creative Leadership Council.
Ovid Therapeutics Inc.
Jason Tardio joins the biopharma company developing therapies for rare diseases as its new Chief Commercial Officer. With vast global commercial leadership experience, Tardio joins Ovid from Novartis, where he served as Vice President and Head of the Multiple Sclerosis franchise. He is charged with creating a highly successful commercial strategy for Ovid’s 2020 pipeline.
Merck alum Iain Martin, PhD joins the Relay team as Vice President of Drug Metabolism and Pharmacokinetics. Ben Wolf, MD, PhD, also joins the growing biotech company as Chief Medical Officer. Dr. Martin has 30 years of experience in the oncology and neuroscience space. He previously served as an Executive Director within the department of pharmacokinetics, pharmacodynamics, and drug metabolism at Merck. Dr. Wolf is a precision oncologist with 20 years’ experience in the biopharmaceutical industry, especially within advancing new oncology programs in the clinic and optimizing patient selection to enable rapid proof of concept and registration. Both are trusted to use recent funding to advance a large pipeline targeting previously untreatable diseases.
Having spent more than a year as Senior VP and Chief Physician-Scientist for respiratory, inflammation, and autoimmunity late-stage development R&D at AstraZeneca, Badrul Chowdhury, MD, PhD, is moving to startup Savana. As the new Chief Medical Officer of the Texas-based biotech focused on orphan lung diseases, Dr. Chowdhury will provide regulatory strategy for a series of mid- to late-stage respiratory meds in the pipeline.
Strongbridge Biopharma plc
The rare disease therapy development company appoints Garheng Kong, MD, PhD, to Lead Independent Director of the company’s Board of Directors. As founder and managing partner of HealthQuest Capital, Dr. Kong has exceptional experience building high-growth companies. The appointment is one step in the company’s strategy for optimizing operational efficiencies in 2020.
As the neurodegenerative disease company enters the clinical stage, it appoints Brigitte Robertson, MD, Chief Medical Officer. Dr. Robertson left her eight-year career leading Shire’s neuroscience division during its buyout by Takeda. Her expertise in global development of multiple industry-leading neurology clinical programs will help Yumanity pursue next-generation therapeutic solutions to combat challenging neurodegenerative diseases.